SHANGHAI FOSUN PHARMACEUTICAL (GROUP)
SSE or SZSE Delayed Price. Currency in CNY
|Number of Shares|
|Company Name||SHANGHAI FOSUN PHARMACEUTICAL (GROUP)|
|MSCI Security Code|
- Jan 11 , 2018
Fosun Pharma Announces Plan to Up Innovation at Home, AbroadShanghai Fosun Pharmaceutical (Group) Co. [SHA:600196] will contribute CNY102 million (USD15.6 million) to its subsidiary, Shanghai Futuo Biotech Development Co., and will join hands with Fosun International Ltd. [HK:0656] to invest USD50 million to establish a new US company.
- Jan 3 , 2018
More Chinese Firms Apply to Conduct Clinical Trials of CAR-T Therapies as China Edges Forward in BiotechnologyChina’s food and drug regulator, the China Food and Drug Administration, has accepted an application by Anhui-based biopharmaceutical company Anke Biotechnology (Group) Co. [SHE:300009] to conduct clinical trials of chimeric antigen receptor-T (CAR-T) therapies. Five Chinese firms applied to test CAR-T therapies last month as China edges ahead of Europe in the field.
- Dec 29 , 2017
Fosun Pharma Plans a Large-Scale Industrial Park in JiangsuHuge pharmaceutical conglomerate Fosun Pharma is planning to build a large-scale industrial park and a new headquarters building in Xuzhou in China’s east-central Jiangsu province.
- Dec 19 , 2017
China’s Home-Grown Cell Therapy Expected to Get Approval in Three Years Will Drop Treatment Costs, Says InsiderChina’s independently-developed first chimeric antigen receptor-T (CAR-T) cell may get approval in three years, and prices could fall below CNY100,000 (USD15,130) to make such therapy more affordable, a Chinese industry insider told Yicai Global.
- Dec 18 , 2017
Chinese CAR-T Products Priced Below USD15,130 May Hit Market in Three Years, Insider SaysChina’s first home-grown chimeric antigen receptor T-cell immunotherapy may get the go-ahead from national regulators in three years, and the price of CAR-T products will drop, perhaps below CNY100,000 (USD15,130), a market insider told Yicai Global.
- Oct 30 , 2017
Fosun Pharmaceutical Plans to Buy Tridem Pharma for USD73 MillionChinese drug industry titan Shanghai Fosun Pharmaceutical Group Co. [SHA:600196] plans to acquire a French firm for USD73 million (EUR63 million). The latter is the third largest pharmaceutical distribution company in the French-speaking region of West Africa.
- Sep 18 , 2017
Fosun Pharmaceutical to Buy 74% Stake in Indian Firm in Revised USD1 Billion OfferShanghai Fosun Pharmaceutical Group Co. [SHA:600196], an arm of Chinese investment company Fosun International Ltd. [HKG:0656], has agreed a revised deal worth USD1.09 billion (CNY7.14 billion) to acquire 74-percent stake in Indian drug company Gland Pharma Ltd. from private equity firm KKR and Co. LP, the conglomerate said in a statement on Sept. 17.
- Sep 12 , 2017
CFDA Policies Won’t Affect Fosun Pharma’s Plan to Bring Overseas CAR-T Therapies to China, CEO SaysShanghai Fosun Pharmaceutical Group Co. [SHA:600196] does not expect government policy to hinder its introduction of foreign biological cellular immune (CAR-T) therapies to China, online media outlet The Paper reported, quoting Wu Yifang, chief executive.
- Sep 1 , 2017
HK Subsidiary of Fosun Pharma Splurges USD66.5 Million on Drug Firm Share PurchaseA Hong Kong-based wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. [SHA:600196] recently purchased a stake in a pharmaceutical research and development company on the Nasdaq Stock Market.
- Aug 17 , 2017
Fosun Pharma and Medidata Reach a Cooperation Agreement to Improve Efficiency in Clinical StudiesChinese healthcare group Shanghai Fosun Pharmaceutical (Group) Co. [SHA:600196] and Medidata Solutions Inc., a world-leading global medical software company, reached a cooperation agreement to raise the operational efficiency of its clinical studies in China.
- Aug 14 , 2017
Shanghai Pharmaceuticals Plans Bid for Stake in US Drug Maker ArborTwo leading Chinese pharmaceutical companies have announced their bid intention to buy into US drug maker Arbor Pharmaceuticals LLC.
- Jul 21 , 2017
One Month After A-Shares Inclusion Into MSCI, 70% of 222 Concept Stocks Rise, 20 Hit New HighIn the small hours of June 21, MSCI announced its decision to incorporate China’s A-shares into the MSCI Emerging Markets Index.
- Jul 17 , 2017
New Leukemia Drug Approval in US Brings Hope to Chinese ResearchersChinese researchers are thrilled at the approval of CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy from Novartis, by the external expert panel of China’s Food and Drug Administration (FDA).
- Jul 6 , 2017
Fosun Pharmaceutical Shares Pick Up After Group Denies Rumors About Founder Guo GuangchangSome rumors suggesting Guo Guangchang, a well-known Chinese entrepreneur and founder of Fosun Group, disappeared caused the company’s share price to slump today. However, share-price decline recovered substantially after Fosun Group and its listed affiliates denied the rumors. As a result, major indexes of the Chinese A-share market rebounded after falling in intraday trading.